Roxanne Lagano Sells 923 Shares of Zoetis Inc. (NYSE:ZTS) Stock

Zoetis Inc. (NYSE:ZTS) EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now directly owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Roxanne Lagano also recently made the following trade(s):

• On Monday, March 18th, Roxanne Lagano sold 923 shares of Zoetis stock. The stock was sold at an average price of $173.33, for a total transaction of $159,983.59.
• On Monday, February 12th, Roxanne Lagano sold 363 shares of Zoetis stock. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62.

Zoetis Stock Performance

Shares of Zoetis stock traded up $1.17 during trading on Thursday, hitting $153.11. 4,772,835 shares of the stock were exchanged, compared to its average volume of 2,989,420. Zoetis Inc. has a 1-year low of $148.48 and a 1-year high of $201.92. The stock has a market capitalization of $70.03 billion, a price-to-earnings ratio of 30.15, a price-to-earnings-growth ratio of 2.34 and a beta of 0.85. The company has a fifty day moving average price of $177.35 and a 200-day moving average price of $180.39. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. During the same quarter last year, the company posted $1.15 EPS. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.13%. Zoetis’s dividend payout ratio (DPR) is currently 34.12%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ZTS. Blue Bell Private Wealth Management LLC grew its stake in Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the last quarter. Evermay Wealth Management LLC grew its position in shares of Zoetis by 439.3% during the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in shares of Zoetis by 430.8% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC acquired a new position in shares of Zoetis during the 1st quarter worth approximately $26,000. Finally, Webster Bank N. A. grew its position in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. Stifel Nicolaus cut their price target on shares of Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Piper Sandler reissued an “overweight” rating and set a $195.00 price target (down from $220.00) on shares of Zoetis in a research report on Tuesday. The Goldman Sachs Group boosted their price target on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Barclays boosted their price target on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $221.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.